Galapagos NV ADR (GLPG NASDAQ) stock market data APIs
$31.0638
0.25(0.8%)
as of July 18, 2025
Try our APIs with
free plan!
Galapagos NV ADR Financial Data Overview
Price chart is built with
Anychart
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Prev. Close
31.0638
Open
31.3187
High
31.6931
Low
30.9277
52 wk Range
22.36-31.39
Market Cap
2 027 M
Shares Outstanding
65 897 K
Revenue
288 M
EPS
0
Beta
-0.01
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galapagos NV ADR data using free add-ons & libraries
Get Galapagos NV ADR Fundamental Data
Galapagos NV ADR Fundamental data includes:
- Net Revenue: 288 M
- EBITDA: -276 281 760
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-23
- EPS/Forecast: -0.2283
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galapagos NV ADR News
New
CRISPR Therapeutics' SWOT analysis: gene-editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-editing therapies, stands at a critical juncture as it navigates the complexities of bringing revolutionary t...
Galapagos Reaches Analyst Target Price
In recent trading, shares of Galapagos NV (Symbol: GLPG) have crossed above the average analyst 12-month target price of $27.70, changing hands for $27.71/share. When a stock reaches the target an an...
Galapagos Appoints Aaron Cox as Chief Financial Officer
Galapagos NV Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET...
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Galapagos NV Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
